On Being with Krista Tippett
Gül Dölen – Psychedelic Science and Radical Healing
On Being with Krista Tippett
•March 5, 2026•0 min
0
On Being with Krista Tippett•Mar 5, 2026
Why It Matters
The breakthrough evidence positions psychedelics as a viable, fast‑acting treatment for severe mental‑health disorders, reshaping clinical practice and influencing drug‑policy reform worldwide.
Key Takeaways
- •Psychedelic trials show rapid relief for treatment-resistant depression.
- •Dölen’s lab links serotonin receptors to neural plasticity.
- •Clinical studies report lasting PTSD symptom reduction.
- •Cross‑political alliances emerge around psychedelic policy reform.
Pulse Analysis
The resurgence of psychedelic research marks a pivotal shift in mental‑health treatment, driven by a wave of rigorously designed clinical trials that challenge conventional pharmacology. Over the past decade, regulatory agencies in the United States and Europe have granted breakthrough‑therapy designations to compounds like psilocybin and MDMA, accelerating patient access while maintaining stringent safety protocols. This evolving landscape has attracted substantial venture capital, fostering a new biotech sector focused on developing standardized, scalable psychedelic medicines for disorders that have long resisted existing interventions.
At the forefront of this scientific renaissance, Gül Dölen’s laboratory elucidates the neurobiological mechanisms that underlie psychedelic efficacy. By mapping how serotonin‑2A receptor activation triggers synaptic remodeling and enhances cortical connectivity, her team provides concrete evidence that these substances promote adaptive neural plasticity. Such insights bridge the gap between subjective therapeutic experiences and measurable brain changes, reinforcing the credibility of psychedelic‑assisted therapy within the broader neuroscience community and informing best‑practice treatment protocols.
The broader implications extend beyond individual patient outcomes to societal and policy realms. As empirical data accumulate, lawmakers are reconsidering prohibitionist frameworks, exploring de‑criminalization and insurance reimbursement models. Healthcare systems anticipate integrating psychedelic clinics, which could alleviate the economic burden of chronic mental‑illness care. Continued interdisciplinary collaboration—uniting neuroscientists, clinicians, ethicists, and legislators—will be essential to translate these promising findings into safe, equitable, and sustainable therapeutic options.
Episode Description
From Krista:
The word “trauma” is used so widely at present, arguably too widely. But it bespeaks a tenor of our shared reality. This episode is a journey inside what I've come to see as a parallel universe unfolding, where our species is unlocking knowledge about ourselves and capacities for radical healing of the most extreme trauma and distress. These findings are even giving rise to dramatic healing alliances across political and social lines that are inflamed in the culture at large.
At universities and research laboratories around the U.S. and the world, there are countless clinical studies, yielding results it’s hard not at times to call miraculous — for complex PTSD, long-term addiction, treatment-resistant depression. What I’m talking about are therapeutically-administered treatments with plant medicines and chemical compounds we call psychedelic or empathogenic.
Use those words, and many of us — including me until not that long ago — might become wary. Like all forces of great power, these can cut in every direction — the dark and the light of the human condition. But the conversation you are about to hear, with one of the leading neuroscientists in this field, revolves around serious, important research in settings designed for careful, beneficial human effect. Gül Dölen's groundbreaking contribution to all of us is in her fascinating insight into what psychedelically-assisted therapies are revealing about the workings of the human brain and the brain's capacity to change and the human capacity for major transformation altogether. The potential consequences of this science are intimate and civilizational at once. I see them as a stunning ray of hope in a struggling world.
I interviewed Gül Dölen at the 2025 Aspen Ideas Festival.
Find an excellent transcript of this show, edited by humans, on our show page.
Sign yourself and others up for The Pause to be on our mailing list for all things On Being and to receive Krista's monthly Saturday newsletter, including a heads up on new episodes, special offerings, recommendations, and event invitations.
Gül Dölen leads the Dölen Lab at U.C. Berkeley, where she is a Professor and the Bob & Renee Parsons Endowed Chair in the Department of Neuroscience and the Department of Psychology at the Berkeley Center for the Science of Psychedelics and the Helen Wills Neuroscience Institute. She also maintains an Adjunct Professorship in Neuroscience and Neurology at the Johns Hopkins University, School of Medicine.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Show Notes
0
Comments
Want to join the conversation?
Loading comments...